Navigation Links
Optimer Pharmaceuticals Announces Key Additions to Management Team
Date:1/10/2011

r holds a Ph.D. in philosophy, health administration from Columbia Southern, a Master of Public Administration with a specialization in health care from C.W. Post College, and a B.S. in, medical biology also from C.W. Post College.

Hemal Shah has spent more than 10 years in HEOR at Boehringer Ingelheim Pharmaceuticals, most recently as Executive Director, where she was focused on the hospital market for the launch of Spivira® for a chronic obstructive pulmonary disease.  She held positions of increasing responsibility in HEOR, implementing HEOR tools including medication adherence, healthcare reforms, health related quality of life research, health economic model development, and pharmacoeconomic analyses to support arguments for commercialization. Shah received her Doctor of Pharmacy from Rutgers State University and holds a B.S. from the University of Connecticut.

Dr. Womelsdorf has more than 15 years of experience in business development roles at Cyclacel Pharmaceuticals, Johnson & Johnson (J&J), F. Hoffmann-La Roche, Baxter International and, most recently, with his own consulting firm.  As the Vice President, Business Development at Cyclacel, he was responsible for all aspects of corporate and business development and licensing including the repositioning of key programs. During his tenure at J&J, Dr. Womelsdorf closed multiple transactions, including a deal with MGI Pharma that gave J&J rights outside North America to Dacogen™ (decitabine), a late stage oncology product with utility in Myelodysplastic Syndromes, Acute Myeloid Leukemia and other cancers. He was appointed to the Board of Tibotec Therapeutics, J&J's oncology and virology company, where he helped oversee the transition of the Company to a commercial entity culminating in the successful launch of Prezista™ (darunivir), a novel protease inhibitor for the treatment of HIV. Prior to joining J&J, he worked as a Global Licensing Director f
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
2. Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection
3. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
4. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
5. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
6. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
8. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
9. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
10. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015 Celtaxsys, Inc., a clinical stage pharmaceutical ... rare and orphan inflammatory disease indications, announced today that ... Drug Administration (FDA) to begin a Phase 2 clinical ... adult CF patients in the US. The regulatory submissions ... will be filed soon after. This groundbreaking clinical ...
(Date:7/6/2015)... SOUTH SAN FRANCISCO, Calif. , July ... ), a leading global pharmaceutical company, and Oculeve, a ... for dry eye disease, today announced that they have ... Oculeve in an all-cash transaction.  Under the terms of ... million upfront payment and commercialization milestone payments related to ...
(Date:7/6/2015)... -- China Information Technology, Inc. (the "Company" or "CNIT") ... platform, exchange, and big data solutions in ... its mobile app for Healthcare One Pass, ushering in ... devices. The Company jointly hosted the launch ceremony with ... Shenzhen News Net.   The mobile app for ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... ... Anticancer Drug, HOUSTON, ... to families, workplaces and communities, and many,Houstonians are aware of ... the CHRISTUS Stehlin Foundation for,Cancer Research, a nationally recognized leader ...
Journalists and other readers should disregard the news release "Oramed,Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository",OTC:ORMP, issued earlier today. The release was transmitted...
Cached Medicine Technology:Local Research Foundation Achieves Milestone in Fight Against Cancer 2Local Research Foundation Achieves Milestone in Fight Against Cancer 3
(Date:7/7/2015)... , ... July 07, 2015 , ... ... Ellen Purdy as the company’s new Chief Financial Officer, effective July 6th, 2015. ... experience in companies ranging from a multi-billion dollar, global chemical company to early ...
(Date:7/7/2015)... Annapolis, MD (PRWEB) , ... July 07, 2015 ... ... quality and an official accrediting body as designated by the Centers for Medicare ... improved user experience and to enhance compatibility with mobile devices. , The most ...
(Date:7/7/2015)... ON (PRWEB) , ... July 07, 2015 , ... On ... is effective immediately and permits the use of gluten-free claims for gluten free oats ... prospect of expanding the Gluten-Free Certification Program (GFCP) to include gluten-free oat ...
(Date:7/7/2015)... ... July 07, 2015 , ... CareSync proudly announces today ... by the White House as a “Champion of Change” for Precision Medicine on ... the Champions of Change program recognizes Gleason and eight other extraordinary individuals who ...
(Date:7/6/2015)... ... July 06, 2015 , ... For over twenty years, Doctors ... injury victims. Throughout the company’s history the goal has been to be a ... in their recovery. And while Doctors on Liens has certainly achieved that goal, ...
Breaking Medicine News(10 mins):Health News:Office Practicum Announces new CFO 2Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 2Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 4Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 3Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 3
... City Hotel and Casino will host the 3rd ... ReceptionATLANTIC CITY, N.J., Feb. 17 The American ... are teaming up on Wednesday, February 25, 2009 ... Blood Donor Campaign awards reception.(Logo: http://www.newscom.com/cgi-bin/prnh/20090217/DC71647LOGO ...
... Six studies published in the past year by a Cornell ... -- as well as daily helpings of other fruits and ... one of his recent papers, published in the Journal ... Cornell associate professor of food science and a member of ...
... (Feb. 17, 2009) A research project at Rice ... long-standing medical mystery that may link cardiovascular disease, osteoporosis and ... thank the rat. , The recent paper in Artery ... team reports they have found that common rats with a ...
... TORONTO, Feb. 17 /PRNewswire/ - Sentinelle Medical Inc., ... software and Siemens Healthcare today announced an OEM ... agreement, Siemens will sell the "Sentinelle Vanguard for ... Espree, MAGNETOM(R) Avanto and MAGNETOM(R) Symphony, A Tim(TM) ...
... by wartime conditions, researchers say , , TUESDAY, Feb. 17 ... can be exacerbated by combat conditions in Iraq and ... being evacuated for treatment, a new report finds. , ... responsible for poor morale and combat ineffectiveness, the researchers ...
... from The University of Nottingham are taking to the streets ... are nearly twice the national average. , Reducing high levels ... which ranks third highest in the country after Corby and ... Control Studies and Professor in Health Policy and Promotion at ...
Cached Medicine News:Health News:The American Red Cross Recognizes Atlantic City Casinos 2Health News:In flurry of studies, researcher details role of apples in inhibiting breast cancer 2Health News:Mutant rats offer clues to medical mystery 2Health News:Mutant rats offer clues to medical mystery 3Health News:Sentinelle Medical Enters OEM Distribution Agreement with Siemens AG 2Health News:Sentinelle Medical Enters OEM Distribution Agreement with Siemens AG 3Health News:Skin Woes Take Toll on U.S. Combat Troops 2Health News:Skin Woes Take Toll on U.S. Combat Troops 3Health News:Investigating a community where smoking rates are double the national average 2
... Split Splint reduces PIP joint or DIP joint ... to put on. Soft gel-lining cushions injured fingers ... begin earlier for faster, more successful therapy results. ... and at night to maintain gains in motion. ...
... FoamWrap Final Flexion Wraps restore full PIP ... or when lost due to arthritic changes. ... foam-lined material hugs the finger to prevent ... restore motion. One size. Sold in packages ...
One splint does it all....
... of minor knee pain like arthritis, tendonitis ... with the motion of the knee, applying ... tendon and assisting in the relief of ... with high density foam padding molds itself ...
Medicine Products: